Urothelial Carcinoma With Pulmonary Tumor Thrombotic Microangiopathy After Chemotherapy for Hodgkin Lymphoma
Open Access
- 27 August 2022
- journal article
- research article
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 14 (8) , 327-333
Abstract
Treatment-related second malignancies (SMs) remain a major concern in long-term survivors of Hodgkin lymphoma (HL). In this report, the autopsy findings of a patient with HL, who was in complete remission after chemotherapy but expired of pulmonary tumor thrombotic microangiopathy (PTTM) caused by urothelial carcinoma of the renal pelvis (UCRP), were described. A 78-year-old Japanese man with a history of classical HL developed irreversible heart failure about 2.5 years after chemotherapy. The patient expired shortly after being admitted due to ineffective treatment for heart failure. However, the cause of death was not determined. The patient’s autopsy findings revealed UCRP in the left kidney, as well as infiltration around the inferior vena cava and lungs, but no HL recurrence. The primary causes of mortality were respiratory and heart failure due to PTTM. Therefore, it is essential to consider the risk of SMs and search for them in patients with HL after chemotherapy. J Clin Med Res. 2022;14(8):327-333 doi: https://doi.org/10.14740/jocmr4802Keywords
This publication has 19 references indexed in Scilit:
- Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2016
- Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trialsThe Lancet Haematology, 2015
- Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens2014
- Association of Anthracycline-Related Cardiac Histological Lesions With NADPH Oxidase Functional PolymorphismsThe Oncologist, 2013
- Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical TrialsJournal of Clinical Oncology, 2013
- Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: An analysis of 6 autopsy cases and review of the literaturePathology - Research and Practice, 2010
- Long-term risk of second malignancy after treatment of Hodgkin’s disease: the influence of treatment, age andfollow-up timeAnnals of Oncology, 2002
- Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factorsBlood, 2002
- Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's DiseaseNew England Journal of Medicine, 1996
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979